Featured Research

from universities, journals, and other organizations

Every Patient Is Unique: Individualized Therapies For Non-Hodgkin's Lymphoma

Date:
June 16, 2008
Source:
Society of Nuclear Medicine
Summary:
Positron emission tomography could be an important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan -- the first radioimmunotherapy treatment approved for use by the US Food and Drug Administration. PET imaging allows practitioners to identify patients who could be treated, predict how they would respond and identify relapses early in patients with follicular lymphoma.

Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT)--the first radioimmunotherapy treatment approved for use by the U.S. Food and Drug Administration, said researchers at SNM's 55th Annual Meeting. PET imaging allows practitioners to identify patients who could be treated, predict how they would respond and identify relapses early in patients who have follicular lymphoma, a common type of slow-growing lymphoma.

"This study illustrates how PET could be used to advance the goal of personalized medicine--identifying and targeting the right treatment for each individual," said Stefano Fanti, professor of nuclear medicine at the Policlinico S. Orsola--Universitΰ di Bologna in Bologna, Italy, and a researcher of this study. "The functional data provided by PET are essential for determining stages of cancer, detecting disease relapses and evaluating how patients respond to particular therapies. Our study clearly indicates that the next step--using PET for predicting how patients will respond to treatment--can be achieved."

In the United States, about 65,000 new cases of non-Hodgkin's lymphoma are diagnosed every year. The number of new cases is on the rise, especially among older people and people whose immune systems are not functioning normally. Those at risk include people who have had organ transplants and those with human immunodeficiency virus (HIV).

Non-Hodgkin's lymphomas are a diverse group of cancers that develop in B or T lymphocytes, which are white blood cells that normally defend the body against bacteria and other pathogens. This group of cancers is actually the cause of more than 20 diseases, which have distinct appearances under the microscope and different clinical courses. Most non-Hodgkin's lymphomas are from B cells.

IT is a monoclonal antibody used in conjunction with radioactive medications to treat non-Hodgkin's lymphoma patients who have relapsed after treatment or for those with slow-growing forms of the disease such as follicular lymphoma. While there have been studies to investigate the usefulness of PET in patients with lymphoma and research into the effectiveness of radioimmunotherapy, no data were available regarding the role of PET in determining whether patients would be good candidates for IT.

In their study, Fanti and his team examined 38 non-Hodgkin's lymphoma patients who were treated with IT after a relapse. PET scans were taken before IT treatment and then three months after treatment began. All patients had a final assessment at six months using clinical data.

Results indicated that the first set of PET scans detected the relapse and extent of the disease in all of the patients. At the six-month follow up, 89 percent of the patients were either in complete or partial remission after the IT treatment. Comparison of PET data on the extent of patients' disease at relapse and their response after three months indicated a higher rate of response to the treatment in patients whose cancer was limited. In all of the cases, the findings of the PET scans at three months were consistent with the clinical findings at six months.

Scientific Paper 584: P. Castellucci, G. Montini, I. Santi, V. Ambrosini, R. Franchi, S. Fanti, Nuclear Medicine, Policlinico S. Orsola, Bologna, Italy; P. Zinzani, M. Tani, V. Stefoni, Haematology, Policlinico S. Orsola, Bologna, Italy; D. Rubello, Ospedale S. Maria della Misericordia, Rovigo, Italy; "FDG-PET in the Assessment of Patients with non-Hodgkin's Lymphoma Treated by Ibritumomab Tiuxetan," SNM's 55th Annual Meeting, June 14-18, 2008.

 


Story Source:

The above story is based on materials provided by Society of Nuclear Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society of Nuclear Medicine. "Every Patient Is Unique: Individualized Therapies For Non-Hodgkin's Lymphoma." ScienceDaily. ScienceDaily, 16 June 2008. <www.sciencedaily.com/releases/2008/06/080616115735.htm>.
Society of Nuclear Medicine. (2008, June 16). Every Patient Is Unique: Individualized Therapies For Non-Hodgkin's Lymphoma. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2008/06/080616115735.htm
Society of Nuclear Medicine. "Every Patient Is Unique: Individualized Therapies For Non-Hodgkin's Lymphoma." ScienceDaily. www.sciencedaily.com/releases/2008/06/080616115735.htm (accessed April 16, 2014).

Share This



More Health & Medicine News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Outbreak Now Linked To 121 Deaths

Ebola Outbreak Now Linked To 121 Deaths

Newsy (Apr. 15, 2014) — The ebola virus outbreak in West Africa is now linked to 121 deaths. Health officials fear the virus will continue to spread in urban areas. Video provided by Newsy
Powered by NewsLook.com
Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) — A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com
How Mt. Everest Helped Scientists Research Diabetes

How Mt. Everest Helped Scientists Research Diabetes

Newsy (Apr. 15, 2014) — British researchers were able to use Mount Everest's low altitudes to study insulin resistance. They hope to find ways to treat diabetes. Video provided by Newsy
Powered by NewsLook.com
Carpenter's Injury Leads To Hundreds Of 3-D-Printed Hands

Carpenter's Injury Leads To Hundreds Of 3-D-Printed Hands

Newsy (Apr. 14, 2014) — Richard van As lost all fingers on his right hand in a woodworking accident. Now, he's used the incident to create a prosthetic to help hundreds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins